ArticleScientific reports2018
Allopurinol partially prevents disuse muscle atrophy in mice and humans.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- The association of allopurinol with persistent physical disability and frailty in a large community based older cohort.Journal of the American Geriatrics Society · 2023Trial
- Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies.Cardiovascular drugs and therapy · 2026Review
- Physical activity during COVID-19 pandemic: A 5-year retrospect.Sports medicine and health science · 2025Review
- Serum essential elements and muscle health in Chinese adults: a community-based study.Nutrition & metabolism · 2025Article
- Xanthine oxidase inhibitor allopurinol preserves cardiac function after experimental malocclusion induced by occlusal disharmony in mice.The journal of physiological sciences : JPS · 2025Article
- Article
- Allopurinol attenuates development of Porphyromonas gingivalis LPS-induced cardiomyopathy in mice.PloS one · 2025Article
- Uric acid formation is driven by crosstalk between skeletal muscle and other cell types.JCI insight · 2024Article
- Zebrafish Models for Skeletal Muscle Senescence: Lessons from Cell Cultures and Rodent Models.Molecules (Basel, Switzerland) · 2022Review
- Regulation of aging by balancing mitochondrial function and antioxidant levels.The journal of physiological sciences : JPS · 2022Article
- Mechanism of reduced muscle atrophy via ketone body (D)-3-hydroxybutyrate.Cell & bioscience · 2022Article
- Sarcopenia in rheumatic disorders: what the radiologist and rheumatologist should know.Skeletal radiology · 2022Review
- CUL3 and COPS5 Related to the Ubiquitin-Proteasome Pathway Are Potential Genes for Muscle Atrophy in Mice.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis.Frontiers in medicine · 2022Article
- Role of ATP-Small Heat Shock Protein Interaction in Human Diseases.Frontiers in molecular biosciences · 2022Review
- Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.International journal of molecular sciences · 2021Review
- Redox-related biomarkers in physical exercise.Redox biology · 2021Review
- Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Article
- Approaching Gravity as a Continuum Using the Rat Partial Weight-Bearing Model.Life (Basel, Switzerland) · 2020Review
- Redox modulation of muscle mass and function.Redox biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disuse muscle wasting will likely affect everyone in his or her lifetime in response to pathologies such as joint immobilization, inactivity or bed rest. There are no good therapies to treat it. We previously found that allopurinol, a drug widely used to treat gout, protects muscle damage after exhaustive exercise and results in functional gains in old individuals. Thus, we decided to test its effect in the prevention of soleus muscle atrophy after two weeks of hindlimb unloading in mice, and lower leg immobilization following ankle sprain in humans (EudraCT: 2011-003541-17). Our results show that allopurinol partially protects against muscle atrophy in both mice and humans. The protective effect of allopurinol is similar to that of resistance exercise which is the best-known way to prevent muscle mass loss in disuse human models. We report that allopurinol protects against the loss of muscle mass by inhibiting the expression of ubiquitin ligases. Our results suggest that the ubiquitin-proteasome pathway is an appropriate therapeutic target to inhibit muscle wasting and emphasizes the role of allopurinol as a non-hormonal intervention to treat disuse muscle atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.